Numax (motavizumab) / AstraZeneca - LARVOL DELTA

Impact of RSV Prevention in Infancy on Prevalence of Asthma Among 9-14-Year-old Native American Children in the Southwest United States. (PubMed, Pediatr Infect Dis J) - "Asthma-related outcomes occurred less frequently among children who received motavizumab compared with placebo in infancy; however, these findings were not statistically significant, related to insufficient study power. The potential for reduction in asthma related to the prevention of RSV should be further evaluated in larger studies, especially given the elevated asthma prevalence observed in Native American children in this study."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

The Cumulative Variations of Respiratory Syncytial Virus Fusion Protein (F) in Ten Consecutive Years in China. (PubMed, Infect Dis Rep) - "There were cumulative variations of the RSV F gene, especially at some binding sites of antigenic sites."

Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Immunogenicity of a recombinant plant-produced respiratory syncytial virus F subunit vaccine in mice. (PubMed, Biotechnol Rep (Amst)) - "The recombinant RSV-F Fc fusion protein was recognized by the monoclonal antibody Motavizumab specific against RSV-F protein...According to our results, the plant-produced RSV-F Fc fusion protein is immunogenic in mice. These preliminary findings, demonstrate the immunogenicity of plant-based RSV-F Fc fusion protein, however, further preclinical studies such as antigen dose and adjuvant optimization, safety, toxicity, and challenge studies in animal models are necessary in order to prove the vaccine efficacy."

Journal • Preclinical • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Inhaled "Muco-Trapping" Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections. (PubMed, Adv Sci (Weinh)) - "An inhalable "muco-trapping" variant of motavizumab (Mota-MT), a potent neutralizing mAb against RSV F is engineered...Mota-MT-treated lambs exhibited reduced bronchiolitis, neutrophil infiltration, and airway remodeling than lambs receiving placebo or intramuscular palivizumab. The findings underscore inhaled delivery of muco-trapping mAbs as a promising strategy for the treatment of RSV and other acute respiratory infections."

Journal • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection. (PubMed, Cochrane Database Syst Rev) - "We are very uncertain about the effect of immunoglobulins on mortality. We are moderately certain that use of immunoglobulins in hospitalised infants and children may result in little to no difference in the length of hospitalisation. Immunoglobulins may result in little to no difference in adverse events, the need for or duration of mechanical ventilation, supplemental oxygen, or admission to the intensive care unit, though we are less certain about this evidence and the true effect of immunoglobulins on these outcomes may differ markedly from the estimated effect observed in this review. All trials were conducted in high-income countries, and data from populations in which the rate of death from RSV infection is higher are lacking."

Journal • Review • Critical care • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Immunoinformatics aided approach for predicting potent cytotoxic T cell epitopes of respiratory syncytial virus. (PubMed, J Biomol Struct Dyn) - "The only approved therapies for RSV are the monoclonal antibodies palivizumab and its derivative motavizumab. From our findings on selected T-cell-specific RSV antigen epitopes, notably the four epitopes confirmed to exhibit stable binding by molecular dynamics. The prediction pipeline used in this study represents an effective way to screen the immunogenic epitopes from other pathogens.Communicated by Ramaswamy H. Sarma."

Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis. (PubMed, JAMA Netw Open) - "In this study, motavizumab, nirsevimab, and palivizumab were associated with substantial benefits in the prevention of RSV infection, without a significant increase in adverse events compared with placebo. However, more research is needed to confirm the present conclusions, especially for safety and cost-effectiveness."

Clinical • Journal • Retrospective data • Review • Critical care • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Backbone and side-chain resonance assignments of the NISTmAb-scFv and antigen-binding study. (PubMed, Biomol NMR Assign) - "Here, we present the resonance assignment of the single chain variable fragment, NISTmAb-scFv, that was engineered by linking the variable domains of the heavy and light chains of the NISTmAb. Also, addition of a peptide, corresponding to the target antigen of motavizumab, to samples of NISTmAb-scFv has induced chemical shift perturbations on residues lining the antigen binding interface thereby indicating proper folding of the NISTmAb-scFv."

Journal • Immunology • Oncology • Respiratory Diseases

Molecular Modeling Predicts Novel Antibody Escape Mutations in the Respiratory Syncytial Virus Fusion Glycoprotein. (PubMed, J Virol) - "In this study, we used an approach that combines molecular dynamics simulations with FoldX to estimate changes in free energy in F protein folding and binding to the motavizumab antibody upon each possible amino acid change...Because no vaccine is currently available, monoclonal antibodies are used to prevent severe RSV disease in high-risk infants. While it is known that RSV evolves to avoid recognition by antibodies, screening tools that can predict which changes to the virus may lead to antibody resistance are greatly needed."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness (clinicaltrials.gov) - P=N/A; N=118; Completed; Sponsor: MedImmune LLC; Phase classification: P2 ➔ P=N/A

Clinical • Phase classification • Respiratory Diseases • Respiratory Syncytial Virus Infections • PCR

Adeno-Associated Virus Vector-Mediated Expression of Antirespiratory Syncytial Virus Antibody Prevents Infection in Mouse Airways. (PubMed, Hum Gene Ther) - "In this study, we demonstrate that intranasal delivery of adeno-associated virus serotype 9 (AAV9) vector expressing palivizumab or motavizumab, a second-generation version of palivizumab, significantly reduced the viral load in the lungs of the BALB/c mouse model of RSV infection. Notably, we demonstrate that AAV9 vector-mediated prophylaxis against RSV was effective despite the presence of serum-circulating neutralizing AAV9 antibodies. These findings substantiate the feasibility of repeatedly administering AAV9 vector to the airway for seasonal prophylaxis against RSV, thereby expanding the application of vectored delivery of mAbs as an effective prophylaxis strategy against various airborne viruses."

Journal • Preclinical • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness (clinicaltrials.gov) - P2; N=12; Terminated; Sponsor: MedImmune LLC; Completed ➔ Terminated; The study was terminated early due to an inability to enroll the planned number of participants

Clinical • Trial termination • Respiratory Diseases • Respiratory Syncytial Virus Infections • PCR

An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus. (PubMed, NPJ Vaccines) - "Atomic-level structures of epitopes targeted by RSV-neutralizing antibodies are now known, including that bound by Motavizumab and its clinically used progenitor Palivizumab. The vaccine protects preclinical animal models from RSV infection and lung pathology typical of vaccine-derived disease enhancement. The results suggest that the development of a safe and effective synthetic epitope-specific RSV vaccine may be feasible by combining this conformationally stabilized peptide and synthetic nanoparticle delivery system."

Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections